

Jocelyne Fares, MD

Clinical Assistant Professor

Clerkship Director, Internal Medicine MEDIII and MEDIV

Ext. 5511

jocelyne.fares@laumcrh.com



Dr. Jocelyne Fares is a Clinical Assistant Professor - Diabetes, Endocrinology & Metabolism. LAU Medical Center –RH and a clerkship Director 3d and 4th year medical students LAU- school of medicine.

Dr. Fares received her M.D. degree in 1996 and completed a fellowship program in Endocrinology and Metabolism at the American University of Beirut Medical Center in 2002. Following her fellowship, she joined the Research Program at the American University of Beirut Medical Center for two years and earned her Master's degree in Epidemiology from the same institution in 2004.

Dr. Fares has furthered her expertise with various certifications and training, including the IOF Bone Densitometry Training and Certification Course in Beirut (October 7, 2000), the Human Participant Protections Education for Research

Teams online course sponsored by the National Institute of Health (NIH) (May 1, 2004), and the ISCD Certificate as Clinical Densitometrist (March 2007). Additionally, she participated in the Johns Hopkins University Continuing Medical Educational Activity on hypertension management in the Eastern Mediterranean Region (October 29, 2010). She completed a Leadership Certificate Program (February 2019 – June 2019) and the Essential Skills in Medical Education Assessment (ESMEA) course at AMEE 2019 in Vienna, Austria (August 24-28, 2019).

Dr. Fares has published extensively in endocrinology. Her key works include studies on the effects of gender, puberty, and vitamin D on bone remodeling (*Bone*, 2003), and the role of HbA1c in predicting diabetic nephropathy (*International Journal of Diabetes Mellitus*, 2010). She also investigated the combination of diabetes and thyroid dysfunction (*Revue Médicale Libanaise*, 1998), and contributed to research on hyperparathyroidism-jaw tumor syndrome (*Journal of Internal Medicine*, 2005). Her work on hepatitis C virus genotypes in Lebanese patients has been accepted for publication in *Infection and*

Epidemiology and International Journal of Epidemiology. Additionally, she studied the efficacy of generic rosuvastatin (*Annals of Saudi Medicine*, 2017), sodium-glucose co-transporter protein 2 inhibitors-induced hypercalcemia (*AACE Clinical Case Reports*, 2022), and minimal autonomous cortisol secretion (*Endocrine, Metabolic & Immune Disorders - Drug Targets*, 2024).

Dr. Fares is actively involved in several professional organizations. She has been a member of the Lebanese Society of Endocrinology, Diabetes, and Lipids since September 2004, and the Osteos Society since March 2007. Additionally, she has been affiliated with the American Association of Clinical Endocrinologists (AACE) International since December 2020.